The neuroprotective effects of caffeine in neurodegenerative diseases

CNS Neuroscience and Therapeutics

Volumn 23, Issue 4, 2017, Pages 272-290

  Kolahdouzan, Mahshad ^a,b   Hamadeh, Mazen J ^a,b  

^a York University   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

adenosine receptor; Alzheimer disease; amyotrophic lateral sclerosis; caffeine; dosage; Huntington disease; neurodegenerative disease; neuroprotection; Parkinson disease

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CAFFEINE; CALCIUM; CYTOCHROME P450 1A2; ESTROGEN; PHOSPHODIESTERASE; RILUZOLE; NEUROPROTECTIVE AGENT;

ALLELE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOE EPSILON4 GENE; APOPTOSIS; CALCIUM TRANSPORT; COFFEE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FOOD COMPOSITION; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MACHADO JOSEPH DISEASE; MOTOR NEURON DISEASE; NEUROPROTECTION; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEPLETION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; ANIMAL; NEURODEGENERATIVE DISEASES;

ANIMALS; CAFFEINE; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 85015722418     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12684     Document Type: Review

References (107)

1. Xu F, Liu P, Pekar JJ, Lu H. Does acute caffeine ingestion alter brain metabolism in young adults? NeuroImage. 2015;110C:39-47.
2. Ullrich S, de Vries Y, Kühn S, Repantis D, Dresler M, Ohla K. Feeling smart: effects of caffeine and glucose on cognition, mood and self-judgment. Physiol Behav. 2015;151:629-637.
3. Pong NY, Or TCT, Ip NY. Plant alkaloids as drug leads for Alzheimer's disease. Neurochem Int. 2015;89:260-270.
4. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal Toxicol. 2003;27:520-522.
5. Fox GP, Wu A, Yiran L, Force L. Variation in caffeine concentration in single coffee beans. J Agric Food Chem. 2013;61:10772-10778.
6. Caffeine. Centre of Addiction and Mental Health. 2013. p. 1.
7. Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain Beta-amyloid production. Neuroscience. 2006;142:941-952.
8. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol. 2002;40:1243-1255.
9. Ritchie K, Carriere I, de Mendonca A, et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007;69:536-545.
10. van Gelder BM, Buijsse B, Tijhuis M, et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007;61:226-232.
11. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009;16:85-91.
12. Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta. 1996;1282:63-70.
13. Mishra J, Kumar A. Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease. Pharmacol Rep. 2014;66:1148-1155.
14. Ullah F, Ali T, Kim MO. Caffeine prevents D-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. Neurochem Int. 2015;90:114-124.
15. Carelli-Alinovi C, Ficarra S, Russo AM, et al. Involvement of acetylcholinesterase and protein kinase C in the protective effect of caffeine against β-amyloid-induced alterations in red blood cells. Biochimie. 2016;121:52-59.
16. Spiff AI, Uwakwe AA. Activation of human erythrocyte glutathione-s- transferase (EC. 2.5.1.18) by caffeine (1,3,7- trimethylxanthine). J Appl Sci Environ Manag. 2003;7:45-48.
17. Chee HK, Oh SJ. Molecular vibration-activity relationship in the agonism of adenosine receptors. Genomics Inform. 2013;11:282-288.
18. Moro S, Deflorian F, Spalluto G, et al. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chem Commun (Camb). 2003;24:2949-2956.
19. Pedata F, Dettori I, Coppi E, et al. Purinergic signalling in brain ischemia. Neuropharmacology. 2016;104:105-130.
20. Dias RB, Rombo DM, Ribeiro JA, Henley JM, Sebastião AM. Adenosine: setting the stage for plasticity. Trends Neurosci. 2013;36:248-257.
21. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res. 2000;87:1095-1102.
22. Fredholm BB, Abbracchio MP, Burstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994;46:143-156.
23. Halldner L, Adén U, Dahlberg V, Johansson B, Ledent C, Fredholm BB. The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology. 2004;46:1008-1017.
24. DallIgna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol. 2003;138:1207-1209.
25. Shi D, Nikodijevic O, Jacobson KA, Daly JW. Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. Cell Mol Neurobiol. 1993;13:247-261.
26. Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. Neurobiol Dis. 2004;24:1521-1529.
27. Giunta S, Andriolo V, Castorina A. Dual blockade of the A1 and A2A adenosine receptor prevents amyloid beta toxicity in neuroblastoma cells exposed to aluminum chloride. Int J Biochem Cell Biol. 2014;54C:122-136.
28. Mohamed RA, Agha AM, Nassar NN. SCH58261 the selective adenosine A2A receptor blocker modulates ischemia reperfusion injury following bilateral carotid occlusion: role of inflammatory mediators. Neurochem Res. 2012;37:538-547.
29. Sawynok J. Adenosine receptor targets for pain. Neuroscience. 2016;338:1-18.
30. Mohamed R, Agha A, Abdel-Rahman A, Nassar N. Role of adenosine A2A receptor in ischemia reperfusion injury: signaling to extracellular signal-regulated protein kinase. Neuroscience. 2016;314:145-159.
31. Kaster MP, Machado NJ, Silva HB, et al. Caffeine acts through neuronal adenosine A 2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proc Natl Acad Sci. 2015;112:201423088.
32. Pedata F, Pugliese AM, Coppi E, et al. Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia. Mediators Inflamm. 2014;2014:805198.
33. Dobson KL, Jackson C, Balakrishnan S, Bellamy TC. Caffeine modulates vesicle release and recovery at cerebellar parallel fibre terminals, independently of calcium and cyclic AMP signalling. PLoS One. 2015;10:1-23.
34. Liu J, Supnet C, Sun S, et al. The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels. 2014;8:230-242.
35. Fill M, Copell JA. Ryanodine receptor calcium release channels. Physiol Rev. 2002;82:893-922.
36. Yoshimura H. The potential of caffeine for functional modification from cortical synapses to neuron networks in the brain. Curr Neuropharmacol. 2005;3:309-316.
37. Kong H, Jones PP, Koop A, et al. Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor. Biochem J. 2009;414:441-452.
38. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83-133.
39. Garrett BE, Griffiths RR. The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav. 1997;57:533-541.
40. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2009;147(S1):S252-S257.
41. Simonin C, Duru C, Salleron J, et al. Association between caffeine intake and age at onset in Huntington's disease. Neurobiol Dis. 2013;58:179-182.
42. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in alzheimer's disease. Nat Rev. 2002;3:862-872.
43. Basurto-Islas G, Blanchard J, Tung YC, et al. Therapeutic benefits of a component of coffee in a rat model of Alzheimer disease. Neurobiol Aging. 2014;35:2701-2712.
44. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445-453.
45. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer ‘s disease ? Eur J Neurol. 2002;9:377-382.
46. Kim Y, Mi S, Myung S. Caffeine intake from coffee or tea and cognitive disorders : a meta-analysis of observational studies. Neuroepidemiology. 2015;769:51-63.
47. Popoli P, Pintor A, Domenici MR, et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci. 2002;22:1967-1975.
48. Laurent C, Burnouf S, Ferry B, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry. 2014;2016:97-107.
49. Chu YF, Chang WH, Black RM, et al. Crude caffeine reduces memory impairment and amyloid β1-42 levels in an Alzheimer's mouse model. Food Chem. 2012;135:2095-2102.
50. Arendash GW, Mori T, Cao C, et al. Caffeine reverses cognitive impairment and decreases brain amyloid levels in aged alzheimer's disease mice. J Alzheimers Dis. 2009;17:661-680.
51. Rajendran P, Bhatt A, Manthuruthil S, Pericherla S. Caffeine and Alzheimer's disease. Int J Biol Med Res. 2013;3:3513-3514.
52. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by Rifampicin and caffeine as a possible protection mechanism against Alzheimer's disease. J Alzheimers Dis. 2012;31:151-165.
53. Han K, Jia N, Li J, Yang L, Min LQ. Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. Mol Med Rep. 2013;8:737-740.
54. Ghoneim FM, Khalaf HA, Elsamanoudy AZ, El-khair SMA, Helaly AMN. Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease. Int J Clin Exp Pathol. 2015;8:7710-7728.
55. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res. 2011;1417:127-136.
56. Dragicevic N, Delic V, Cao C, et al. Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. Neuropharmacology. 2012;63:1368-1379.
57. Sato A, Terata K, Miura H, et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol. 2005;288:H1633-H1640.
58. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
59. Prasanthi JRP, Bhanu D, Marwarha G, et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med. 2010;49:1212-1220.
60. Boerwinkle E, Utermannt G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apoprotein E and cholesterol metabolism. Am J Hum Genet. 1988;42:104-112.
61. Hall K, Murrell J, Ogunniyi A, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology. 2006;66:223-227.
62. Kumar PM, Paing SST, Li H, et al. Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson's Disease. Sci Rep. 2015;5:15492.
63. Bagga P, Chugani AN, Patel AB. Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: a 13C NMR study. Neurochem Int. 2016;92:24-35.
64. Prediger RDS. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 2010;20:s205-s220.
65. Hayashi A, Matsunaga N, Okazaki H, et al. A disruption mechanism of the molecular clock in a MPTP mouse model of parkinson's disease. Neuromolecular Med. 2013;15:238-251.
66. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79:651-658.
67. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283:2674-2679.
68. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012;175:1200-1207.
69. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr Gerontol Int. 2014;14:430-439.
70. Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. 2012;27:1276-1282.
71. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007;22:2242-2248.
72. Ascherio A, Chen H, Schwarzschild M, Zhang S, Colditz G, Speizer F. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003;60:790-795.
73. Greene N, Lassen CF, Rugbjerg K, Ritz B. Reproductive factors and Parkinson's disease risk in Danish women. Eur J Neurol. 2014;21:1168, e68.
74. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732-738.
75. Xu K, Xu Y, Brown-Jermyn D, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci. 2006;26:535-541.
76. Sonsalla PK, Wong L-Y, Harris SL, et al. Delayed caffeine treatment nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp Neurol. 2012;234:482-487.
77. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21:1-6.
78. Nakaso K, Ito S, Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett. 2008;432:146-150.
79. Arita R, Yanagi Y, Honda N, et al. Caffeine increases tear volume depending on polymorphisms within the adenosine A2a receptor gene and cytochrome P450 1A2. Ophthalmology. 2012;119:972-978.
80. El-Sohemy A, Cornelis MC, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype and risk of myocardial infarction. Genes Nutr. 2007;2:155-156.
81. Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol. 1994;47:1767-1776.
82. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39:936-940.
83. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007;63:537-546.
84. Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. Am J Clin Nutr. 2012;96:665-671.
85. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini E. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr. 2007;21:190-200.
86. Cornelis MC, Byrne EM, Esko T, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry. 2015;20:647-656.
87. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010;167:475-481.
88. Ng SK, Higashimori H, Tolman M, Yang Y. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2015;267:115-122.
89. Nascimento F, Pousinha PA, Correia AM, Gomes R, Sebastião AM, Ribeiro JA. Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase. PLoS One. 2014;9:e104081.
90. Moghimi E, Solomon JA, Gianforcaro A, Hamadeh MJ. Dietary vitamin D3 restriction exacerbates disease pathophysiology in the spinal cord of the G93A mouse model of amyotrophic lateral sclerosis. PLoS One. 2015;10:e0126355.
91. Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39-59.
92. Fondell E, ÉiJ O, Fitzgerald KC, et al. Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: results from five cohort studies. Amyotroph Lateral Scler Frontemporal Degener. 2014;2015:1-6.
93. Nascimento F, Sebastião AM, Ribeiro JA. Presymptomatic and symptomatic ALS SOD1 (G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission. Purinergic Signal. 2015;11:471-480.
94. Van Kan HJM, Groeneveld CJ, Kalmijn S, Spieksma M, Van Den Berg LH, Guchelaar HJ. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005;59:310-313.
95. Sanderink G-J, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997;282:1465-1472.
96. Mievis S, Blum D, Ledent C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2011;41:570-576.
97. Blum D, Hourez R, Galas M, Popoli P, Schiffmann SN. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2003;2:366-374.
98. Alfinito PD, Wang S-P, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci. 2003;23:10982-10987.
99. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener. 2011;6:1-12.
100. Li X, Liu H, Fischhaber PL, Tang T-S. Toward therapeutic targets for SCA3: insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance. Prog Neurobiol. 2015;132:34-58.
101. Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480:543-548.
102. Gonçalves N, Simões AT, Cunha RA, De Almeida LP. Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Ann Neurol. 2013;73:655-666.
103. Arendash GW, Cao C. Caffeine and coffee as therapeutics against Alzheimer's disease. J Alzheimers Dis. 2010;20(Suppl. 1):117-126.
104. Freedman ND, Park Y, Abnet CC, Hollenbeck A, Sinha R. Association of Coffee Drinking with total and all cause mortality. N Engl J Med. 2012;366:1891-1904.
105. Ford B. Pain in Parkinson's disease. Mov Disord. 2012;27:485-491.
106. Handy CR, Krudy C, Boulis N, Federici T. Pain in amyotrophic lateral sclerosis: a Neglected aspect of disease. Neurol Res Int. 2011;2011:1-8.
107. Bell DG, McLellan TM. Exercise endurance 1, 3, and 6 h after caffeine ingestion in caffeine users and nonusers. J Appl Physiol. 2002;93:1227-1234.